HRP980203B1 - Modified tnf "alpha" molecules, dna encoding such modified tnf "alpha" molecules and vaccines comprising such modified tnf "alpha" molecules and dna - Google Patents

Modified tnf "alpha" molecules, dna encoding such modified tnf "alpha" molecules and vaccines comprising such modified tnf "alpha" molecules and dna

Info

Publication number
HRP980203B1
HRP980203B1 HR980203A HRP980203A HRP980203B1 HR P980203 B1 HRP980203 B1 HR P980203B1 HR 980203 A HR980203 A HR 980203A HR P980203 A HRP980203 A HR P980203A HR P980203 B1 HRP980203 B1 HR P980203B1
Authority
HR
Croatia
Prior art keywords
alpha
molecules
tnfalpha
modified tnf
modified
Prior art date
Application number
HR980203A
Other languages
English (en)
Inventor
Martin
Soren Mouritsen
Henrik Elsner
Iben Dalum
Original Assignee
Ferring Farma Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Farma Lab filed Critical Ferring Farma Lab
Publication of HRP980203A2 publication Critical patent/HRP980203A2/hr
Publication of HRP980203B1 publication Critical patent/HRP980203B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HR980203A 1997-04-15 1998-04-15 Modified tnf "alpha" molecules, dna encoding such modified tnf "alpha" molecules and vaccines comprising such modified tnf "alpha" molecules and dna HRP980203B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK41897 1997-04-15

Publications (2)

Publication Number Publication Date
HRP980203A2 HRP980203A2 (en) 1998-12-31
HRP980203B1 true HRP980203B1 (en) 2003-04-30

Family

ID=8093298

Family Applications (1)

Application Number Title Priority Date Filing Date
HR980203A HRP980203B1 (en) 1997-04-15 1998-04-15 Modified tnf "alpha" molecules, dna encoding such modified tnf "alpha" molecules and vaccines comprising such modified tnf "alpha" molecules and dna

Country Status (29)

Country Link
US (1) US7118750B1 (OSRAM)
EP (1) EP0975668B1 (OSRAM)
JP (1) JP2001521386A (OSRAM)
KR (1) KR100522289B1 (OSRAM)
CN (1) CN1178955C (OSRAM)
AR (1) AR012427A1 (OSRAM)
AT (1) ATE326481T1 (OSRAM)
AU (1) AU743400B2 (OSRAM)
BR (1) BR9811462A (OSRAM)
CA (1) CA2289476A1 (OSRAM)
CZ (1) CZ9903657A3 (OSRAM)
DE (1) DE69834556T2 (OSRAM)
DK (1) DK0975668T3 (OSRAM)
EE (1) EE9900461A (OSRAM)
ES (1) ES2264569T3 (OSRAM)
HR (1) HRP980203B1 (OSRAM)
HU (1) HUP0001930A3 (OSRAM)
IL (1) IL132281A0 (OSRAM)
NO (1) NO995002L (OSRAM)
NZ (1) NZ337955A (OSRAM)
PL (1) PL194221B1 (OSRAM)
RU (1) RU2241715C2 (OSRAM)
SI (1) SI0975668T1 (OSRAM)
SK (1) SK285639B6 (OSRAM)
TR (1) TR199902562T2 (OSRAM)
TW (1) TW510921B (OSRAM)
UA (1) UA72440C2 (OSRAM)
WO (1) WO1998046642A1 (OSRAM)
ZA (1) ZA983148B (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
WO2000051637A1 (en) * 1999-03-02 2000-09-08 Centocor, Inc. ANTI-TNFα ANTIBODIES IN THERAPY OF ASTHMA
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
SK722002A3 (en) 1999-07-20 2003-02-04 Pharmexa As Method for down-regulating GDF-8 activity
WO2001097837A1 (en) * 2000-06-21 2001-12-27 Ferring Bv Solubilised protein vaccines
WO2003075951A2 (en) * 2002-03-11 2003-09-18 Pharmexa A/S Novel application of vaccination against tnf-alpha
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
MXPA06009805A (es) 2004-02-27 2007-04-02 Vaxconsulting Peptidos de interleucina 1 beta y factor de necrosis tumoral alfa y metodo de tratamiento utilizando los mismos.
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
KR101465456B1 (ko) 2005-05-16 2014-11-27 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
KR20100084623A (ko) * 2007-09-25 2010-07-27 인터벳 인터내셔널 비.브이. 골관절염 치료용 백신
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2011057099A2 (en) 2009-11-05 2011-05-12 The Uab Research Foundation Treating basal-like genotype cancers
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
CA2820837A1 (en) 2010-12-08 2012-06-14 Neovacs Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
CN102539778A (zh) * 2010-12-24 2012-07-04 北京义翘神州生物技术有限公司 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒
JP2011201902A (ja) * 2011-05-19 2011-10-13 Wyeth Llc 可溶性Ａ−βに対する抗体を生成させるための能動免疫
CN103376327A (zh) * 2012-04-28 2013-10-30 通用电气公司 检测抗体或融合蛋白的浓度的方法
AU2016256876B2 (en) 2015-05-05 2021-02-04 Rubicon Biotechnology Llc Cancer immunotherapeutic
CN106279403B (zh) * 2016-08-16 2019-06-11 长春市海兰深生物医学技术有限公司 一种检测天然肺癌相关抗体的组合物、试剂盒和方法
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3750056T2 (de) 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU634379B2 (en) 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
CA2119089A1 (en) 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden

Also Published As

Publication number Publication date
TW510921B (en) 2002-11-21
HUP0001930A2 (hu) 2000-09-28
RU2241715C2 (ru) 2004-12-10
CA2289476A1 (en) 1998-10-22
KR20010006416A (ko) 2001-01-26
HRP980203A2 (en) 1998-12-31
UA72440C2 (en) 2005-03-15
PL336295A1 (en) 2000-06-19
EE9900461A (et) 2000-06-15
AR012427A1 (es) 2000-10-18
ES2264569T3 (es) 2007-01-01
CN1252809A (zh) 2000-05-10
HUP0001930A3 (en) 2001-10-29
AU743400B2 (en) 2002-01-24
ZA983148B (en) 1999-10-15
ATE326481T1 (de) 2006-06-15
JP2001521386A (ja) 2001-11-06
SK285639B6 (sk) 2007-05-03
PL194221B1 (pl) 2007-05-31
CZ9903657A3 (cs) 2001-09-12
TR199902562T2 (xx) 2000-02-21
AU7030398A (en) 1998-11-11
DE69834556T2 (de) 2007-05-10
NO995002L (no) 1999-12-15
US7118750B1 (en) 2006-10-10
BR9811462A (pt) 2000-09-12
IL132281A0 (en) 2001-03-19
NO995002D0 (no) 1999-10-14
EP0975668A1 (en) 2000-02-02
SK140999A3 (en) 2000-06-12
CN1178955C (zh) 2004-12-08
WO1998046642A1 (en) 1998-10-22
NZ337955A (en) 2000-09-29
DE69834556D1 (de) 2006-06-22
HK1022918A1 (en) 2000-08-25
KR100522289B1 (ko) 2005-10-19
DK0975668T3 (da) 2006-09-25
EP0975668B1 (en) 2006-05-17
SI0975668T1 (sl) 2007-02-28

Similar Documents

Publication Publication Date Title
PL336295A1 (en) Modified tnfalpha molecule, dna encoding such molecule and vaccine comprising such tnfalpha molecule and such dna
EP0752886B1 (en) Inducing antibody response against self-proteins with the aid of foreign t-cell epitopes
HUP9801122A2 (hu) Osteoprotegerin
BG102343A (en) Recombinant anti-cd4 antibodies for therapy in hyman medicine
CA2289912A1 (en) Human receptor proteins; related reagents and methods
DE60332645D1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
NZ508381A (en) Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
RU94045919A (ru) Антитела, клетки, полипептид, днк векторы, способ получения полипептида, способ получения антитела, фармацевтическая композиция
PL363071A1 (pl) Sposoby i kompozycje dla zmniejszenia replikacji HIV-1
BR9408006A (pt) Molécula de ácido nucléico isolada e purificada vetor e vetor de express o adaptados para transformaçao de hospedeiro hospedeiro transformado proteina receptora "transferrin" recombinante ou fragmento ou análogo da mesma proteina Tbpl purificada e isolada proteina Tbp2 purificada e isolada peptídeo composiç o imunogênica vetor ativo para fornecimento de proteina receptora "transferrin" vetor de plasmideo linhagem de haemophilus processo para produzir proteina Tbp2 ou Tbpl purificada e isolada
ES2241040T3 (es) Proteinas hibridas que forman heterodimeros.
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
ATE371671T1 (de) Rekombinantes allergen, seine fragmente und die damit korrespondierenden dna-moleküle, vektoren, und diese dna-moleküle enthaltenden wirte, und dignostische und therapeutische verwendungen besagter allergene und fragmente
IL93397A (en) Pancreatic islet cell antigen protein or peptides, their preparation by molecular cloning, their use in the diagnosis of insulin dependent diabetes mellitus and pharmaceutical compositions comprising said antigens
AU5776799A (en) Modified hcv peptide vaccines
PT93178B (pt) Agente proteico anticanceroso
EP1277837A3 (de) Epididymis-spezifische DNA-Sequenzen und deren Verwendung
WO1996009391A3 (en) Dna sequence and protein of the non-structural reading frame i of the human parvovirus b19
EP0378929A3 (en) Membrane proteins and peptides of haemophilus influenzae type b
KR930703444A (ko) 어류 황체화 호르몬-방출 호르몬 동족체
Fischer et al. Synthetic peptide antigens of tetanus toxin
NZ505350A (en) DNA encoding a tumour antigen peptide (43 kDa) for diagnosis or treatment of tumours
AU2001281943A1 (en) The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof
AU2001251410A1 (en) 12303, a novel human twik molecule and uses thereof
JPS61100598A (ja) 抗原性ペプチド化合物

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: PHARMEXA A/S, DK

ODRP Renewal fee for the maintenance of a patent

Payment date: 20070223

Year of fee payment: 10

PBON Lapse due to non-payment of renewal fee

Effective date: 20080416